Partnering with Bigpharma: The definitive guide to partnering interests, contacts & agreements

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Bigpharma - The Top 50

Chapter 3 - Most active bigpharma dealmakers

• 3.1 Bigpharma M&A activity
• 3.2 Bigpharma partnering

Chapter 4 - Top bigpharma deals - 2000-7

• 4.1 Bigpharma M&A
• 4.2 Bigpharma partnering

Chapter 5 - Submitting Opportunities to Bigpharma

• 5.1 How to submit an opportunity
• 5.2 Opportunity submission template
• 5.3 Sending emails
• 5.4 Face to face at partnering events
• 5.5 Online submission forms

Chapter 6 - Forthcoming bigpharma partnering events

• 6.1 Forthcoming events

Chapter 7 - Bigpharma company - therapy locator

• 7.1 How to use the therapy matrix tables
• 7.2 Therapeutic area definitions
• 7.3 Bigpharma - Therapeutic target matrix - marketed and pipeline compounds
• 7.5 Bigpharma - Therapeutic target matrix - expressed partnering interests
• 7.6 Bigpharma - Therapeutic target matrix - recent deals - 2005-2007

Chapter 8 - Bigpharma Company Profiles

• 8.1 How to use company profiles
• 8.2 Field definitions
• 8.3 Company profiles
  • Abbott
  • Actavis
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Barr Pharmaceuticals
  • Baxter International
  • Bayer
  • Biogen Idec
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Chugai
  • CSL
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Forest Laboratories
  • Genentech
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • King
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck Serono KGaA
  • Mitsubishi-Tanabe
  • Mundipharma
  • Novartis AG
  • Novo Nordisk
  • Nycomed Pharma
  • Otsuka
  • Pfizer
  • Procter & Gamble
  • Ratiopharm
  • Roche
  • Sanofi-Aventis
  • Schering Plough
  • Servier
  • Shire
  • Solvay
  • Stada
  • Takeda
  • Teva
  • UCB
  • Watson
  • Wyeth

About Current�@Partnering

Recent report titles from Current�@Partnering

Order Form - Reports

Order Form - Report Update Subscription

Order form - Company Dealmaking Profiles

Order Form - CD-Rom

• Figure 1: Bigpharma - top 50 by pharma revenues 2007
• Figure 2: Leading Bigpharma M&A companies, 2005-7
• Figure 3: Leading Bigpharma partnering companies, 2005-7
• Figure 4: Leading M&A deals involving bigpharma by value, 2005-7
• Figure 5: Leading partnering deals by value, 2005-7
• Figure 6: Typical partnering opportunity submission template
• Figure 7: Partnering events 2008-9
• Figure 8: Therapeutic area definitions
• Figure 9: Therapeutic target matrix - marketed and pipeline compounds
• Figure 10: Therapeutic target matrix - expressed partnering interests
• Figure 11: Therapeutic target matrix - recent deals 2005-7
• Figure 12: Company profile template and definitions used in report
• Figure 13: Abbott - Dealmaking frequency 2000-2007
• Figure 14: Abbott - recent deals (2005-2008) by deal type
• Figure 15: Abbott - recent deals (2005 - 2008) by stage of development
• Figure 16: Abbott - recent deals (2005 - 2008) by therapy area
• Figure 17: Recent Abbott partnering deals (2003-2008) where contract document available
• Figure 18: Actavis - Dealmaking frequency 2000-2007
• Figure 19: Actavis - recent deals (2005-2008) by deal type
• Figure 20: Actavis - recent deals (2005 - 2008) by stage of development
• Figure 21: Actavis - recent deals (2005 - 2008) by therapy area
• Figure 22: Recent Actavis partnering deals (2003-2008) where contract document available
• Figure 23: Alcon Labs dealmaking frequency 2000-2007
• Figure 24: Alcon Labs - recent deals (2005 - 2008) by deal type
• Figure 25: Alcon Labs - recent deals (2005 - 2008) by stage of development
• Figure 26: Alcon Labs - recent deals (2005 - 2008) by therapy area
• Figure 27: Recent Alcon Labs partnering deals (2003-2008) where contract document available
• Figure 28: Allergan - Dealmaking frequency 2000-2007
• Figure 29: Allergan - recent deals (2005-2008) by deal type
• Figure 30: Allergan - recent deals (2005 - 2008) by stage of development
• Figure 31: Allergan - recent deals (2005 - 2008) by therapy area
• Figure 32: Recent Allergan partnering deals (2003-2008) where contract document available
• Figure 33: Amgen - Dealmaking frequency 2000-2007
• Figure 34: Amgen - recent deals (2005-2008) by deal type
• Figure 35: Amgen - recent deals (2005 - 2008) by stage of development
• Figure 36: Amgen - recent deals (2005 - 2008) by therapy area
• Figure 37: Recent Amgen partnering deals (2003-2008) where contract document available
• Figure 38: Astellas - Dealmaking frequency 2000-2007
• Figure 39: Astellas - recent deals (2005-2008) by deal type
• Figure 40: Astellas - recent deals (2005 - 2008) by stage of development
• Figure 41: Astellas - recent deals (2005 - 2008) by therapy area
• Figure 42: Recent Astellas partnering deals (2003-2008) where contract document available
• Figure 43: AstraZeneca - Dealmaking frequency 2000-2007
• Figure 44: AstraZeneca - recent deals (2005-2008) by deal type
• Figure 45: AstraZeneca - recent deals (2005 - 2008) by stage of development
• Figure 46: AstraZeneca - recent deals (2005 - 2008) by therapy area
• Figure 47: Recent AstraZeneca partnering deals (2003-2008) where contract document available
• Figure 208: Barr - Dealmaking frequency 2000-2007
• Figure 219: Barr - recent deals (2005-2008) by deal type
• Figure 220: Barr - recent deals (2005 - 2008) by stage of development
• Figure 221: Barr - recent deals (2005 - 2008) by therapy area
• Figure 222: Recent Barr partnering deals (2003-2008) where contract document available
• Figure 48: Baxter - Dealmaking frequency 2000-2007
• Figure 49: Baxter - recent deals (2005-2008) by deal type
• Figure 50: Baxter - recent deals (2005 - 2008) by stage of development
• Figure 51: Baxter - recent deals (2005 - 2008) by therapy area
• Figure 52: Recent Baxter partnering deals (2003-2008) where contract document available
• Figure 53: Bayer - Dealmaking frequency 2000-2007
• Figure 54: Bayer - recent deals (2005-2008) by deal type
• Figure 55: Bayer - recent deals (2005 - 2008) by stage of development
• Figure 56: Bayer - recent deals (2005 - 2008) by therapy area
• Figure 57: Recent Bayer partnering deals (2003-2008) where contract document available
• Figure 58: Biogen Idec - Dealmaking frequency 2000-2007
• Figure 59: Biogen Idec - recent deals (2005 - 2008) by deal type
• Figure 60: Biogen Idec - recent deals (2005 - 2008) by stage of development
• Figure 61: Biogen Idec - recent deals (2005 - 2008) by therapy area
• Figure 62: Recent Biogen Idec partnering deals (2003-2008) where contract document available
• Figure 63: Boehringer Ingelheim - Dealmaking frequency 2000-2007
• Figure 64: Boehringer Ingelheim - recent deals (2005 - 2008) by deal type
• Figure 65: Boehringer Ingelheim - recent deals (2005 - 2008) by stage of development
• Figure 66: Boehringer Ingelheim - recent deals (2005 - 2008) by therapy area
• Figure 67: Recent Boehringer Ingelheim partnering deals (2003-2008) where contract document available
• Figure 68: Bristol-Myers Squibb - Dealmaking frequency 2000-2007
• Figure 69: Bristol-Myers Squibb - recent deals (2005 - 2008) by deal type
• Figure 70: Bristol-Myers Squibb - recent deals (2005 - 2008) by stage of development
• Figure 71: Bristol-Myers Squibb - recent deals (2005 - 2008) by therapy area
• Figure 72: Recent Bristol-Myers Squibb partnering deals (2003-2008) where contract document available
• Figure 73: Chugai - Dealmaking frequency 2000-2007
• Figure 74: Chugai - recent deals (2005-2008) by deal type
• Figure 75: Chugai - recent deals (2005 - 2008) by stage of development
• Figure 76: Chugai - recent deals (2005 - 2008) by therapy area
• Figure 77: Recent Chugai partnering deals (2003-2008) where contract document available
• Figure 78: CSL - Dealmaking frequency 2000-2007
• Figure 79: CSL - recent deals (2005-2008) by deal type
• Figure 80: CSL - recent deals (2005 - 2008) by stage of development
• Figure 81: CSL - recent deals (2005 - 2008) by therapy area
• Figure 82: Recent CSL partnering deals (2003-2008) where contract document available
• Figure 208: DaiichiSankyo - Dealmaking frequency 2000-2007
• Figure 219: DaiichiSankyo - recent deals (2005-2008) by deal type
• Figure 220: DaiichiSankyo - recent deals (2005 - 2008) by stage of development
• Figure 221: DaiichiSankyo - recent deals (2005 - 2008) by therapy area
• Figure 222: Recent DaiichSankyo partnering deals (2003-2008) where contract document available
• Figure 83: Eisai - Dealmaking frequency 2000-2007
• Figure 84: Eisai - recent deals (2005-2008) by deal type
• Figure 85: Eisai - recent deals (2005 - 2008) by stage of development
• Figure 86: Eisai - recent deals (2005 - 2008) by therapy area
• Figure 87: Recent Eisai partnering deals (2003-2008) where contract document available
• Figure 88: Eli Lilly - Dealmaking frequency 2000-2007
• Figure 89: Eli Lilly - recent deals (2005-2008) by deal type
• Figure 90: Eli Lilly - recent deals (2005 - 2008) by stage of development
• Figure 91: Eli Lilly - recent deals (2005 - 2008) by therapy area
• Figure 92: Recent Eli Lilly partnering deals (2003-2008) where contract document available
• Figure 93: Forest - Dealmaking frequency 2000-2007
• Figure 94: Forest - recent deals (2005-2008) by deal type
• Figure 95: Forest - recent deals (2005 - 2008) by stage of development
• Figure 96: Forest - recent deals (2005 - 2008) by therapy area
• Figure 97: Recent Forest partnering deals (2003-2008) where contract document available
• Figure 98: Genentech - Dealmaking frequency 2000-2007
• Figure 99: Genentech - recent deals (2005-2008) by deal type
• Figure 100: Genentech - recent deals (2005 - 2008) by stage of development
• Figure 101: Genentech - recent deals (2005 - 2008) by therapy area
• Figure 102: Recent Genentech partnering deals (2003-2008) where contract document available
• Figure 103: Genzyme - Dealmaking frequency 2000-2007
• Figure 104: Genzyme - recent deals (2005-2008) by deal type
• Figure 105: Genzyme - recent deals (2005 - 2008) by stage of development
• Figure 106: Genzyme - recent deals (2005 - 2008) by therapy area
• Figure 107: Recent Genzyme partnering deals (2003-2008) where contract document available
• Figure 108: Gilead - Dealmaking frequency 2000-2007
• Figure 109: Gilead - recent deals (2005-2008) by deal type
• Figure 110: Gilead - recent deals (2005 - 2008) by stage of development
• Figure 111: Gilead - recent deals (2005 - 2008) by therapy area
• Figure 112: Recent Gilead partnering deals (2003-2008) where contract document available
• Figure 113: GlaxoSmithKline - Dealmaking frequency 2000-2007
• Figure 114: GlaxoSmithKline - recent deals (2005-2008) by deal type
• Figure 115: GlaxoSmithKline - recent deals (2005 - 2008) by stage of development
• Figure 116: GlaxoSmithKline - recent deals (2005 - 2008) by therapy area
• Figure 117: Recent GlaxoSmithKline partnering deals (2003-2008) where contract document available
• Figure 118: Johnson & Johnson - Dealmaking frequency 2000-2007
• Figure 119: Johnson & Johnson - recent deals (2005-2008) by deal type
• Figure 120: Johnson & Johnson - recent deals (2005 - 2008) by stage of development
• Figure 121: Johnson & Johnson - recent deals (2005 - 2008) by therapy area
• Figure 122: Recent Johnson & Johnson partnering deals (2003-2008) where contract document available
• Figure 123: King Pharmaceuticals - Dealmaking frequency 2000-2007
• Figure 124: King - recent deals (2005-2008) by deal type
• Figure 125: King - recent deals (2005 - 2008) by stage of development
• Figure 126: King - recent deals (2005 - 2008) by therapy area
• Figure 127: Recent King partnering deals (2003-2008) where contract document available
• Figure 128: Lundbeck - Dealmaking frequency 2000-2007
• Figure 129: Lundbeck - recent deals (2005-2008) by deal type
• Figure 130: Lundbeck - recent deals (2005 - 2008) by stage of development
• Figure 131: Lundbeck - recent deals (2005 - 2008) by therapy area
• Figure 132: Recent Lundbeck partnering deals (2003-2008) where contract document available
• Figure 133: Menarini - Dealmaking frequency 2000-2007
• Figure 134: Menarini - recent deals (2005-2008) by deal type
• Figure 135: Menarini - recent deals (2005 - 2008) by stage of development
• Figure 136: Menarini - recent deals (2005 - 2008) by therapy area
• Figure 137: Recent Menarini partnering deals (2003-2008) where contract document available
• Figure 138: Merck & Co - Dealmaking frequency 2000-2007
• Figure 139: Merck & Co - recent deals (2005-2008) by deal type
• Figure 140: Merck & Co - recent deals (2005 - 2008) by stage of development
• Figure 141: Merck & Co - recent deals (2005 - 2008) by therapy area
• Figure 142: Recent Merck & Co partnering deals (2003-2008) where contract document available
• Figure 143: Merck KGaA - Dealmaking frequency 2000-2007
• Figure 144: Merck KGaA - recent deals (2005-2008) by deal type
• Figure 145: Merck KGaA - recent deals (2005 - 2008) by stage of development
• Figure 146: Merck KGaA - recent deals (2005 - 2008) by therapy area
• Figure 147: Recent Merck KGaA partnering deals (2003-2008) where contract document available
• Figure 148: Mitsubishi-Tanabe - Dealmaking frequency 2000-2007
• Figure 149: Mitsubishi-Tanabe - recent deals (2005-2008) by deal type
• Figure 150: Mitsubishi-Tanabe - recent deals (2005 - 2008) by stage of development
• Figure 151: Mitsubishi-Tanabe - recent deals (2005 - 2008) by therapy area
• Figure 152: Recent Mitsubishi-Tanabe partnering deals (2003-2008) where contract document available
• Figure 208: Mundipharma - Dealmaking frequency 2000-2007
• Figure 219: Mundipharma - recent deals (2005-2008) by deal type
• Figure 220: Mundipharma - recent deals (2005 - 2008) by stage of development
• Figure 221: Mundipharma - recent deals (2005 - 2008) by therapy area
• Figure 222: Recent Mundipharma partnering deals (2003-2008) where contract document available
• Figure 153: Novartis - Dealmaking frequency 2000-2007
• Figure 154: Novartis - recent deals (2005-2008) by deal type
• Figure 155: Novartis - recent deals (2005 - 2008) by stage of development
• Figure 156: Novartis - recent deals (2005 - 2008) by therapy area
• Figure 157: Recent Novartis partnering deals (2003-2008) where contract document available
• Figure 158: Novo Nordisk - Dealmaking frequency 2000-2007
• Figure 159: Novo Nordisk - recent deals (2005-2008) by deal type
• Figure 160: Novo Nordisk - recent deals (2005 - 2008) by stage of development
• Figure 161: Novo Nordisk - recent deals (2005 - 2008) by therapy area
• Figure 162: Recent Novo Nordisk partnering deals (2003-2008) where contract document available
• Figure 163: Nycomed - Dealmaking frequency 2000-2007
• Figure 164: Nycomed - recent deals (2005-2008) by deal type
• Figure 165: Nycomed - recent deals (2005 - 2008) by stage of development
• Figure 166: Nycomed - recent deals (2005 - 2008) by therapy area
• Figure 167: Recent Nycomed partnering deals (2003-2008) where contract document available
• Figure 168: Otsuka - Dealmaking frequency 2000-2007
• Figure 169: Otsuka - recent deals (2005-2008) by deal type
• Figure 170: Otsuka - recent deals (2005 - 2008) by stage of development
• Figure 171: Otsuka - recent deals (2005 - 2008) by therapy area
• Figure 172: Recent Otsuka partnering deals (2003-2008) where contract document available
• Figure 173: Pfizer - Dealmaking frequency 2000-2007
• Figure 174: Pfizer - recent deals (2005-2008) by deal type
• Figure 175: Pfizer - recent deals (2005 - 2008) by stage of development
• Figure 176: Pfizer - recent deals (2005 - 2008) by therapy area
• Figure 177: Recent Pfizer partnering deals (2003-2008) where contract document available
• Figure 178: Procter & Gamble - Dealmaking frequency 2000-2007
• Figure 179: Procter & Gamble - recent deals (2005-2008) by deal type
• Figure 180: Procter & Gamble - recent deals (2005 - 2008) by stage of development
• Figure 181: Procter & Gamble - recent deals (2005 - 2008) by therapy area
• Figure 182: Recent Procter & Gamble partnering deals (2003-2008) where contract document available
• Figure 208: Ratiopharm - Dealmaking frequency 2000-2007
• Figure 219: Ratiopharm - recent deals (2005-2008) by deal type
• Figure 220: Ratiopharm - recent deals (2005 - 2008) by stage of development
• Figure 221: Ratiopharm - recent deals (2005 - 2008) by therapy area
• Figure 222: Recent Ratiopharm partnering deals (2003-2008) where contract document available
• Figure 183: Roche - Dealmaking frequency 2000-2007
• Figure 184: Roche - recent deals (2005-2008) by deal type
• Figure 185: Roche - recent deals (2005 - 2008) by stage of development
• Figure 186: Roche - recent deals (2005 - 2008) by therapy area
• Figure 187: Recent Roche partnering deals (2003-2008) where contract document available
• Figure 188: Sanofi-Aventis - Dealmaking frequency 2000-2007
• Figure 189: Sanofi-Aventis - recent deals (2005-2008) by deal type
• Figure 190: Sanofi-Aventis - recent deals (2005 - 2008) by stage of development
• Figure 191: Sanofi-Aventis - recent deals (2005 - 2008) by therapy area
• Figure 192: Recent Sanofi-Aventis partnering deals (2003-2008) where contract document available
• Figure 193: Schering Plough - Dealmaking frequency 2000-2007
• Figure 194: Schering Plough - recent deals (2005-2008) by deal type
• Figure 195: Schering Plough - recent deals (2005 - 2008) by stage of development
• Figure 196: Schering Plough - recent deals (2005 - 2008) by therapy area
• Figure 197: Recent Schering Plough partnering deals (2003-2008) where contract document available
• Figure 208: Servier - Dealmaking frequency 2000-2007
• Figure 219: Servier - recent deals (2005-2008) by deal type
• Figure 220: Servier - recent deals (2005 - 2008) by stage of development
• Figure 221: Servier - recent deals (2005 - 2008) by therapy area
• Figure 222: Recent Servier partnering deals (2003-2008) where contract document available
• Figure 198: Shire - Dealmaking frequency 2000-2007
• Figure 199: Shire - recent deals (2005-2008) by deal type
• Figure 200: Shire - recent deals (2005 - 2008) by stage of development
• Figure 201: Shire - recent deals (2005 - 2008) by therapy area
• Figure 202: Recent Shire partnering deals (2003-2008) where contract document available
• Figure 203: Solvay - Dealmaking frequency 2000-2007
• Figure 204: Solvay - recent deals (2005-2008) by deal type
• Figure 205: Solvay - recent deals (2005 - 2008) by stage of development
• Figure 206: Solvay - recent deals (2005 - 2008) by therapy area
• Figure 207: Recent Solvay partnering deals (2003-2008) where contract document available
• Figure 208: Stada - Dealmaking frequency 2000-2007
• Figure 219: Stada - recent deals (2005-2008) by deal type
• Figure 220: Stada - recent deals (2005 - 2008) by stage of development
• Figure 221: Stada - recent deals (2005 - 2008) by therapy area
• Figure 222: Recent Stada partnering deals (2003-2008) where contract document available
• Figure 208: Takeda - Dealmaking frequency 2000-2007
• Figure 209: Takeda - recent deals (2005-2008) by deal type
• Figure 210: Takeda - recent deals (2005 - 2008) by stage of development
• Figure 211: Takeda - recent deals (2005 - 2008) by therapy area
• Figure 212: Recent Takeda partnering deals (2003-2008) where contract document available
• Figure 208: Teva - Dealmaking frequency 2000-2007
• Figure 219: Teva - recent deals (2005-2008) by deal type
• Figure 220: Teva - recent deals (2005 - 2008) by stage of development
• Figure 221: Teva - recent deals (2005 - 2008) by therapy area
• Figure 222: Recent Teva partnering deals (2003-2008) where contract document available
• Figure 213: UCB Group - Dealmaking frequency 2000-2007
• Figure 214: UCB Group - recent deals (2005-2008) by deal type
• Figure 215: UCB Group - recent deals (2005 - 2008) by stage of development
• Figure 216: UCB Group - recent deals (2005 - 2008) by therapy area
• Figure 217: Recent UCB Group partnering deals (2003-2008) where contract document available
• Figure 218: Watson - Dealmaking frequency 2000-2007
• Figure 219: Watson - recent deals (2005-2008) by deal type
• Figure 220: Watson - recent deals (2005 - 2008) by stage of development
• Figure 221: Watson - recent deals (2005 - 2008) by therapy area
• Figure 222: Recent Watson partnering deals (2003-2008) where contract document available
• Figure 223: Wyeth - Dealmaking frequency 2000-2007
• Figure 224: Wyeth - recent deals (2005-2008) by deal type
• Figure 225: Wyeth - recent deals (2005 - 2008) by stage of development
• Figure 226: Wyeth - recent deals (2005 - 2008) by therapy area
• Figure 227: Recent Wyeth partnering deals (2003-2008) where contract document available
• Figure 228: Online partnering resources
• Figure 229: Development and license agreement between Boehringer Ingelheim and Inspire Pharmaceuticals, February 2006